Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mohammad Afzal

Internal Medicine Somerset, KY Medical Doctor

NPI 1245329069 CMS profile 283104

110 Hardin Ln, Suite 2-B, Somerset, KY 42503

Open in the dashboard

General payments

$9,445

719 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mohammad Afzal of Somerset, KY is reported in the CMS Open Payments database as having received $9,445 across 719 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $590 31
2024 General $777 49
2023 General $1,442 104
2022 General $1,411 102
2021 General $1,691 129
2020 General $1,730 136
2019 General $1,804 168

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mohammad Afzal
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Mohammad Afzal were reported at $590. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Mohammad Afzal Internal Medicine median Middle half National median
2019 $1,804 $159 $48–$570 $163
2020 $1,730 $119 $33–$402 $114
2021 $1,691 $135 $37–$521 $132
2022 $1,411 $141 $42–$496 $149
2023 $1,442 $149 $45–$519 $160
2024 $777 $154 $47–$537 $164
2025 $590 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $1,164 47 payments
  2. Pfizer Inc. $1,137 119 payments
  3. Amarin Pharma Inc. $948 70 payments
  4. Lilly USA, LLC $752 61 payments
  5. GlaxoSmithKline, LLC. $736 61 payments
  6. Salix Pharmaceuticals, a division of Bausch Health US, LLC $560 42 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $508 42 payments
  8. Novo Nordisk Inc $414 40 payments
  9. Sunovion Pharmaceuticals Inc. $374 35 payments
  10. Bayer HealthCare Pharmaceuticals Inc. $350 23 payments
  11. Other $2,501 179 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,354 713 payments
  2. Education $90 6 payments
Products named General payments · program years 2019–2025
  1. Vascepa $773 57 payments
  2. FARXIGA $764 19 payments
  3. TRELEGY ELLIPTA $675 55 payments
  4. BREZTRI $595 18 payments
  5. XIFAXAN $560 42 payments
  6. ELIQUIS $510 56 payments
  7. NURTEC ODT $507 41 payments
  8. JARDIANCE $441 37 payments
  9. SYMBICORT $392 12 payments
  10. TRULICITY $390 32 payments
  11. Other $9,006 712 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 242 drugs

Part D claims

22,917

Median for Internal Medicine: 777

Drug cost

$2,495,904

Median for Internal Medicine: $73,373

Branded share of claims

27.3%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 424 $256,982
Jardiance Empagliflozin Brand 323 $223,011
Ozempic Semaglutide Brand 174 $203,689
Farxiga Dapagliflozin Propanediol Brand 235 $200,323
Mounjaro Tirzepatide Brand 118 $142,747
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 123 $110,682
Linzess Linaclotide Brand 124 $96,996
Xarelto Rivaroxaban Brand 102 $93,095
Orencia Clickject Abatacept Brand 12 $72,859
Trulicity Dulaglutide Brand 61 $68,521

The 10 drugs with the highest cost, of 242 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 47 billing codes

Paid by Medicare

$103,186

Of which drugs: $9,526

Medicare patients

283

Average age 73

Services billed

2,270

149 women, 134 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 51%
Depression 45%
Diabetes 43%
Chronic kidney disease 37%
COPD 35%
Ischemic heart disease 34%
Atrial fibrillation 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 80 81 $6,604

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XIFAXAN
$135 — —
NURTEC ODT
$114 16 —
ZAVZPRET
$79 — —
BREZTRI
$65 76 —
VOQUEZNA
$55 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

719 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record